Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination With Standard Doses of Selected Chemotherapies to Patients With Advanced Solid Tumors

NCT00600496 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00600496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00600496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination With Standard Doses of Selected Chemotherapies to Patients With Advanced Solid Tumors
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
December 14, 2007
Completion date
December 18, 2025
Enrollment
140 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms, colon cancer, colon neoplasms, colonic cancer, kidney cancer, lung cancer, melanoma